The Analyst Verdict: Globus Medical In The Eyes Of 7 Experts
Portfolio Pulse from Benzinga Insights
Seven analysts have recently evaluated Globus Medical (NYSE:GMED), with opinions ranging from bullish to bearish. The average 12-month price target has increased by 6.43% to $80.43. Analysts have raised their ratings and price targets, reflecting positive sentiment. Despite strong revenue growth, Globus Medical faces challenges with profitability and returns on equity and assets.
October 14, 2024 | 9:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts have shown a positive sentiment towards Globus Medical, raising ratings and price targets. The average 12-month price target has increased by 6.43% to $80.43. Despite strong revenue growth, the company faces challenges with profitability and returns on equity and assets.
The positive sentiment from analysts, reflected in raised ratings and price targets, suggests a likely short-term increase in GMED's stock price. However, the company's challenges with profitability and returns may temper long-term expectations. The strong revenue growth supports the positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100